bluebird bio, Inc.
(NASDAQ : BLUE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.31%171.581.3%$493.75m
BIIBBiogen Inc.
-1.07%226.651.3%$459.06m
CELGCelgene Corporation
-0.24%95.411.3%$443.43m
GILDGilead Sciences, Inc.
-0.53%66.820.9%$426.05m
ILMNIllumina, Inc.
1.65%314.073.5%$310.21m
REGNRegeneron Pharmaceuticals, Inc.
-0.67%313.152.6%$291.60m
AAgilent Technologies, Inc.
1.91%68.991.6%$213.62m
VRTXVertex Pharmaceuticals Incorporated
-0.56%172.051.9%$178.88m
EXASExact Sciences Corporation
3.35%97.1525.3%$168.49m
ALXNAlexion Pharmaceuticals, Inc.
1.91%127.722.0%$150.45m
BMRNBioMarin Pharmaceutical Inc.
2.14%88.834.3%$118.55m
INCYIncyte Corporation
1.41%81.642.5%$108.48m
SRPTSarepta Therapeutics, Inc.
2.24%120.9014.7%$106.99m
ALNYAlnylam Pharmaceuticals, Inc
2.14%69.369.2%$97.51m
IONSIonis Pharmaceuticals, Inc.
-3.19%65.008.2%$94.07m

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.